Fate Therapeutics Inc
NASDAQ:FATE

Watchlist Manager
Fate Therapeutics Inc Logo
Fate Therapeutics Inc
NASDAQ:FATE
Watchlist
Price: 1.08 USD 5.88%
Market Cap: 124.6m USD
Section:
 

Relative Value

The Relative Value of one FATE stock under the Base Case scenario is hidden USD. Compared to the current market price of 1.08 USD, Fate Therapeutics Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FATE Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

17.5
P/S
P/S
Price to Sales
17.5
vs History
57
vs Industry
49
Median 3Y
12
Median 5Y
28.4
Industry
8.2
Forward
19.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-2.5
Industry
24.2
Forward
-0.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-3.1
Industry
23
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-3
Industry
25.5
More Details
0.5
P/B
P/B
Price to Book Value
0.5
vs History
79
vs Industry
74
Median 3Y
0.9
Median 5Y
1.3
Industry
3.3
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
44
Median 3Y
0.1
Median 5Y
5.7
Industry
8.6
Forward
-14
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
More Details
0.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.6
vs History
14
vs Industry
19
Median 3Y
-0.1
Median 5Y
-0.6
Industry
6.1
Forward
0.7
More Details
0.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.5
vs History
14
vs Industry
17
Median 3Y
-0.1
Median 5Y
-0.6
Industry
6.6
Forward
0.6
More Details
0.8
EV/OCF
EV/OCF
Enterprise Value to OCF
0.8
vs History
15
vs Industry
19
Median 3Y
-0.1
Median 5Y
-0.8
Industry
8.8
More Details
0.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.8
vs History
14
vs Industry
15
Median 3Y
-0.1
Median 5Y
-0.8
Industry
6.8
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
68
Median 3Y
0.1
Median 5Y
0.7
Industry
5.7
More Details

Multiples Across Competitors

FATE Competitors Multiples
Fate Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Fate Therapeutics Inc
NASDAQ:FATE
124.6m USD 17.5 -0.8 0.6 0.5
IL
Can Fite Biopharma Ltd
TASE:CANF
168.5T ILS 61 044 186.9 -4 192 122 -4 113 755 -4 104 597.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 067 817 -161 919.3 -196 621.7 -194 378
US
Abbvie Inc
NYSE:ABBV
389.8B USD 6.5 166.5 16.1 22.9
US
Amgen Inc
NASDAQ:AMGN
175.3B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
153.6B USD 5.3 19 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113B USD 9.7 30.9 22.5 23.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.9 -527.7 -574.6 -559.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD 5.5 17.2 16.3 18.4
AU
CSL Ltd
ASX:CSL
84.9B AUD 3.6 18.9 12.7 15.9
NL
argenx SE
XBRU:ARGX
42.6B EUR 13.8 32.4 55.5 57.1
P/S Multiple
Revenue Growth P/S to Growth
US
Fate Therapeutics Inc
NASDAQ:FATE
Average P/S: 8 646 739.9
17.5
-43%
N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
61 044 186.9
140%
436 029.9
FR
Pharnext SCA
OTC:PNEXF
34 067 817
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
10%
1
US
E
Epizyme Inc
F:EPE
2 067.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
13.8
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Fate Therapeutics Inc
NASDAQ:FATE
Average P/E: 44.3
Negative Multiple: -0.8 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 192 122 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 919.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166.5
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.9
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.4
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Fate Therapeutics Inc
NASDAQ:FATE
Average EV/EBITDA: 19.3
0.6
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 113 755 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 621.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
55.5
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Fate Therapeutics Inc
NASDAQ:FATE
Average EV/EBIT: 21.1
0.5
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 104 597.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 378 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
57.1
N/A N/A

See Also

Summary
FATE intrinsic value, competitors valuation, and company profile.
DCF Valuation
FATE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FATE stock valuation using valuation multiples.
Wall Street Estimates
FATE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FATE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.